The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global H1N1 vaccines market reached a value of US$ 3.4 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 4.6 Billion by 2027, exhibiting at a CAGR of 5.4 % during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
The H1N1 virus is an infectious disease characterized by a persistent cough, high fever, red-watery eyes, body aches and headache. The illness is known to have a detrimental effect on the existing chronic ailments, such as Pneumonia, Chronic Obstructive Pulmonary Disease (COPD) and Bronchitis, and can be fatal in severe cases. H1N1 vaccines are a preventive measure administered through intradermal and intranasal procedures to provide active immunization against the virus.
Increasing incidences of epidemic H1N1 infection and declining immunity of the general population are among the key factors driving the market growth. With increasing age, the risk of developing respiratory tract diseases and immunodeficiency disorders also escalates, thereby increasing the risk of acquiring the H1N1 flu infection. However, extensive research and development in the field of immunology and vaccine technologies coupled with extensive support from global health organizations are expected to promote the distribution of quality vaccines. Moreover, a number of developed countries such as Australia, the United Kingdom, and the United States have also included H1N1 vaccinations under their National Immunization Program (NIP) that has increased the demand for these vaccines. Additionally, technological advancements coupled with a rising awareness amongst patients about preventive methods has also led to a heightened demand for H1N1 vaccines.
IMARC Group provides an analysis of the key trends in each sub-segment of the global H1N1 vaccines market, along with forecasts at the global and regional level from 2022-2027. Our report has categorized the market based on vaccine type, key brands and market type.
Breakup by Vaccine Type
Breakup by Market Type:
Analysis of Key Brands:
Breakup by Region:
The report has also examined the competitive landscape of the market and provides the profiles of the key players operating in the industry.
IMARC Group’s latest report provides a deep insight into the global H1N1 vaccines market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the global H1N1 vaccines industry in any manner.
|Base Year of the Analysis||2021|
|Segment Coverage||Vaccine Type, Key Brands, Market Type, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at